What is the Genomic Variant RUO Report?
The Genomic Variant RUO Report (powered by PierianDx) is a research use only (RUO), pan-cancer solution, summarising DNA variants and RNA fusions from formalin-fixed paraffin embedded (FFPE) specimens profiled on the Illumina TSO-500 Solid Tumour Assay, offered as part of Almac’s DNA-Sequencing Solutions.
The Genomic Variant RUO Report
Genomic Variant Reports are generated for de-identified clinical samples, with one report per sample. Detected genomic variants are classified and visualised in an easy-to-interpret PDF report.
The Genomic Variant Reports also includes reporting of detected levels of emerging immuno-oncology biomarkers – Tumour Mutational Burden (TMB) and Microsatellite Instability (MSI).
All variants are classified and reported into four tiers based on the level of scientific and clinical evidence contained within the PierianDx Clinical Knowledge base:
- Tier I: strong significance
- Tier II: potential significance
- Tier III: unknown significance
- Tier IV: benign variants
Benefits of the Genomic Variant RUO Report
- End-to-end workflow incorporating variant calling, classification and interpretation, visualised in a PDF report
- Easy to understand reports generated quickly from complex NGS data
- Uniform reporting of samples to facilitate downstream translational research
- Reports on the most up-to-date scientific and clinically relevant molecular insights
- Also includes reporting of key immuno-oncology biomarkers – TMB and MSI
Request a PDF example of the Genomic Variant RUO Report
Fill in the contact form below if you are interested in speaking to Almac about the Genomic Variant Report for your biomarker discovery needs. If you would like a PDF example of the report sent to you, simply add this in the comments section.
Note: The results provided in this report are for Research Use Only (RUO). All interpretations are made by the PierianDx Clinical Knowledgebase. The data contained within the Genomic Variant Report must not be used to inform patient treatment decisions. Any actionable mutations will need to be confirmed by the appropriate approved validated assay before being used for treatment decisions